Arcellx Inc   (ACLX)
Other Ticker:  
Price: $62.4300 $3.15 5.314%
Day's High: $64.355 Week Perf: 11.94 %
Day's Low: $ 59.08 30 Day Perf: 15.61 %
Volume (M): 866 52 Wk High: $ 75.10
Volume (M$): $ 54,052 52 Wk Avg: $49.93
Open: $59.54 52 Wk Low: $30.88

 Market Capitalization (Millions $) 3,024
 Shares Outstanding (Millions) 48
 Employees -
 Revenues (TTM) (Millions $) 47
 Net Income (TTM) (Millions $) -130
 Cash Flow (TTM) (Millions $) 72
 Capital Exp. (TTM) (Millions $) 17

Arcellx Inc
Arcellx Inc is a biotechnology company that specializes in developing and commercializing cell therapies for cancer treatment. The company is focused on developing next-generation CAR-T (chimeric antigen receptor T-cell) therapies that are engineered to target and eliminate cancer cells more effectively. Arcellx's technology is designed to enhance the safety and efficacy of CAR-T therapies by incorporating a controllable on-switch and off-switch mechanism, allowing for precise control of the therapy's activity. The company aims to revolutionize cancer treatment by providing more targeted and personalized therapies with improved outcomes for patients.

   Company Address: 25 West Watkins Mill Road Gaithersburg 20878 MD
   Company Phone Number: 327-0603   Stock Exchange / Ticker: NASDAQ ACLX


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Business Update

Arcellx and Kite Surge Forward with Revolutionary Anito-Cel Multiple Myeloma Program Amid Financial Hiccups

Published Fri, May 10 2024 12:47 AM UTC

Arcellx Inc. (NASDAQ: ACLX), based in Redwood City, California, and Kite, a Gilead Company (NASDAQ: GILD), based in Santa Monica, California, have announced their operational updates today on their jointly developed anitocabtagene autoleucel (anito-cel) multiple myeloma program. Despite facing a substantial decline in sequential revenue, Arcellx has continued to prioritize a...

Business Update

Arcellx and Kite Announce Advances in Multiple Myeloma Program, Introduce Global Phase 3 Trial for Innovative Anito-Cel Therapy

Published Thu, May 9 2024 8:47 PM UTC

Arcellx and Kite, a Gilead Company, recently provided updates on their anitocabtagene autoleucel (anito-cel) multiple myeloma program, showcasing significant progress in its development. The collaboration between the two companies aims to develop an innovative treatment option for multiple myeloma patients utilizing Arcellx's novel D-Domain binder. Multiple myeloma is a type...

Arcellx Inc

Arcellx Inc Posts Impressive Revenue of $14.957 Million, Marking Robust Growth in Q3 2023

In recent financial reports, Arcellx Inc announced revenue of $14.957 million in the financial time-frame closing September 30, 2023. While this may seem like a positive result, it is essential to also consider the net loss reported during the same period. Arcellx Inc reported a net loss of $-39.336 million, showing a significant increase from the previous year's deficit of $-92.874 million.
This alarming increase in net loss raises concerns about the company's financial stability and ability to generate profits. Investors must closely examine the factors contributing to this substantial loss and assess the company's ability to address them effectively.
The upcoming financial earnings report on March 28, 2024, will be crucial in understanding how Arcellx Inc plans to address its revenue and profitability issues. Investors will be eager to see if the company has implemented strategic initiatives or made necessary changes to reverse the trend of increasing losses.

Arcellx Inc

Arcellx Inc Delivers Impressive Q2 Revenue Growth of $14.302M, Sets Path for Promising Future

Arcellx Inc Shows Encouraging Revenue Growth for Q2 2023, Future Performance Looks Promising
Arcellx Inc, the leading Biotechnology & Pharmaceuticals company, recently announced its financial results for the April to June 30, 2023 time-frame. The company reported a revenue of $14.302 million during this period, showcasing a strong performance in the market.
In comparison to the same quarter last year, Arcellx Inc displayed significant improvement. While the company had recorded a net loss of $-30.772 million in the corresponding period a year ago, they reported a narrower net loss of $-23.854 million in Q2 2023. This positive development indicates the company's ability to manage expenses more efficiently while generating higher revenue.

Arcellx Inc

Arcellx Inc Announces Impressive Revenue of $17.9 Million, Outpacing Last Year's Figures

Arcellx Inc, a biotechnology company, has reported its financial earnings for the period ending March 31, 2023. The company has managed to generate a total revenue of $17.912 million, which indicates an increase in revenue from last year's financial earnings. However, it also highlighted a net loss of $-27.344 million, which is higher than the $-26.041 million loss incurred the previous year.
Despite reporting a net loss, Arcellx Inc has shown resilience in maintaining its revenue growth. The higher loss is primarily attributed to the company's significant investments in research and development, as well as the costs associated with manufacturing its products.


Arcellx Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com